Peritoneal tuberculosis in the setting of ustekinumab treatment for psoriasis

JAAD Case Reports

Volumn 3, Issue 3, 2017, Pages 230-232

  Lynch, Maeve ^a   Roche, Lisa ^a   Horgan, Mary ^b   Ahmad, Kashif ^a   Hackett, Caitriona ^a   Ramsay, Bart ^a  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

peritoneal tuberculosis; psoriasis; psoriatic arthritis; ustekinumab

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; ISONIAZID; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; LIRAGLUTIDE; METHOTREXATE; PREDNISOLONE; PYRIDOXINE; TUBERCULIN; USTEKINUMAB;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; NARROW BAND IMAGING; PHILIPPINES; PHOTOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SKIN BIOPSY; SKIN TEST; TUBERCULOUS PERITONITIS; ULTRAVIOLET B RADIATION;

EID: 85017464785     PISSN: None     EISSN: 23525126     Source Type: Journal    
DOI: 10.1016/j.jdcr.2017.02.001     Document Type: Article

References (13)

1. 1 Papp, K., Gottlieb, A.B., Naldi, L., et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 14 (2015), 706–714.
2. 2 Harris, J., Keane, J., How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 161 (2010), 1–9.
3. 3 Liao, T.L., Lin, C.H., Chen, Y.M., et al. Different risk of tuberculosis and efficacy of isoniazid prophylaxis in rheumatoid arthritis patients with biologic therapy: A nationwide retrospective cohort study in Taiwan. PLoS One, 11, 2016, e0153217.
4. 4 Leonardi, C.L., Kimball, A.B., Papp, K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371:9625 (2008), 1665–1674.
5. 5 Gottlieb, A., Menter, A., Mendelsohn, A., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet, 376(9752), 2010, 1542.
6. 6 Germann, T., Rude, E., Interleukin-12. Int Arch Allergy Immunol 108 (1995), 103–112.
7. 7 O'Quinn, D.B., Palmer, M.T., Lee, Y.K., Weaver, C.T., Emergence of the Th17 pathway and its role in host defense. Adv Immunol 99 (2008), 115–163.
8. 8 Filipe-Santos, O., Bustamante, J., Chapgier, A., et al. Inborn errors of IL-12/23- and IFN-c-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 18 (2006), 347–361.
9. 9 National Institute for Health and Care Excellence. Tuberculosis. Available from: https://www.nice.org.uk/guidance/ng33/chapter/Recommendations. Accessed March 12, 2017.
10. 10 Al-Badri, M.R., Azar, S.T., Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab 5:2 (2014), 34–38.
11. 11 Kisacik, B., Pamuk, O.N., Onat, A.M., et al. Characteristics predicting tuberculosis risk under tumor necrosis factor-α inhibitors: report from a large multicenter cohort with high background prevalence. J Rheumatol, January 15, 2016 [Epub ahead of print].
12. 12 Tsai, T.F., Ho, J.C., Song, M., et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 63 (2011), 154–163.
13. 13 World Health Organization. Global tuberculosis report 2016. Available from: http://www.who.int/tb/publications/global_report/gtbr2016_annex2.pdf?ua=1. Accessed March 12, 2017.